Antigenic determinants of infective and inactivated human rhinovirus type 2.
Treatment of human rhinovirus type 2 (HRV 2) virions at pH 5, at 56 C or in 2 M urea, produces one or both of two types of subviral particles. These subviral particles sediment at 135S or at 80S and both share what have been designated as C-antigenic determinants; the determinants of native virions have been designated D. These sets of determinants have been contrasted by the techniques of immunodiffusion, complement fixation, and serum blocking, and the results indicate that many or most of the D-determinants are lost in the conversion to C antigenicity. Some of the HRV 2 C-determinants also react, in immunodiffusion and in complement fixation tests, with antisera produced against HRV 1A virions. The inverse reaction has also been detected by complement fixation. Purified natural top component (NTC) of HRV 2 contains C- and, to a lesser extent, D-determinants. The D-determinants of NTC are also, like those of virions, lost upon treatment at pH 5. These results are discussed in terms of a conformational model for the D- to C-antigenic conversion.
D000818:Animals; D002499:Centrifugation, Density Gradient; D003168:Complement Fixation Tests; D003601:Cytotoxicity Tests, Immunologic; D000939:Epitopes; D006358:Hot Temperature; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007106:Immune Sera; D005779:Immunodiffusion; D008954:Models, Biological; D011817:Rabbits / Q000276:immunology; D012229:Rhinovirus / Q000187:drug effects / Q000254:growth & development / Q000276:immunology*; D012703:Serotyping; D014508:Urea / Q000494:pharmacology; D010948:Viral Plaque Assay
D000939:Epitopes; D007106:Immune Sera; D014508:Urea